SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma India informs about closure of trading window

12 Dec 2024 Evaluate
Astrazeneca Pharma India has informed that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Equity Shares of the Company will be closed from December 16, 2024 and the same shall reopen after 48 hours from the declaration of un-audited financial results of the Company for the quarter ending December 31, 2024.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma I Share Price

8572.00 46.90 (0.55%)
17-Apr-2026 10:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1695.00
Dr. Reddys Lab 1223.95
Cipla 1240.50
Zydus Lifesciences 944.65
Lupin 2333.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×